This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ETOPOPHOS
Prostate and other male cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ETOPOPHOS Rx

Generic Name and Formulations:
Etoposide (as phosphate) 100mg/vial; pwd for IV infusion after reconstitution and dilution.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for ETOPOPHOS:

Refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy.

Adult:

See full labeling. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, 50–100mg/m2 per day on Days 1 through 5 to 100mg/m2 per day on Days 1, 3, 5). Repeat course every 3–4 weeks after recovery (esp. myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): see full labeling. Consider dose modification if any myelosuppressive effect due to previous radiation, chemotherapy, or in combination with other drugs.

Children:

Not established.

Warnings/Precautions:

Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Embryo-fetal toxicity. Advise patients to use effective contraception during therapy and for at least 4 months (males) or 6 months (females) after last dose. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid). May potentiate warfarin; monitor INR. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; infertility, others.

How Supplied:

Single-dose vials—1

Indications for ETOPOPHOS:

Small cell lung cancer.

Adult:

See full labeling. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, 35mg/m2 per day for 4 days to 50mg/m2 per day for 5 days). Repeat course every 3–4 weeks after recovery (esp. myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): see full labeling. Consider dose modification if any myelosuppressive effect due to previous radiation, chemotherapy, or in combination with other drugs.

Children:

Not established.

Warnings/Precautions:

Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Embryo-fetal toxicity. Advise patients to use effective contraception during therapy and for at least 4 months (males) or 6 months (females) after last dose. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid). May potentiate warfarin; monitor INR. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; infertility, others.

How Supplied:

Single-dose vials—1

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Fever in adults - red flag symptomsExternal web site

Fever in adults can have potentially serious causes, ranging from sepsis to malignancy. Dr Pipin Singh...

0.50 Credits
Red flags

Bone pain - red flag symptomsExternal web site

In this article Dr Pipin Singh advises on how to identify red flags in patients presenting with bone...

0.50 Credits
Red flags

Pregnancy - red flag symptomsExternal web site

Dr Matthew West covers the red flags to look out for in pregnancy, including back pain, bleeding, headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Bronchiectasis: clinical reviewExternal web site

This article, updated in 2016 by Dr Anthony De Soyza, advises on causes, investigations and managing...

1.50 Credits
Clinical Review

Brugada syndrome: clinical reviewExternal web site

Dr Keith Barnard discusses the aetiology and symptoms of Brugada syndrome. Key learning points for GPs...

1.50 Credits
Clinical Review

Measles: clinical reviewExternal web site

Dr Kirsty Le Doare and Dr Nuria Martinez-Alier describe the signs and symptoms of measles and outline...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »